Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Oncorus (NASDAQ: ONCR ) stock is taking a beating on Monday after revealing plans for an upcoming special shareholder meeting. According to a filing with the Securities and Exchange Commission (SEC), ...
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023....
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced...
Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announce...
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announ...
After losing some value lately, a hammer chart pattern has been formed for Oncorus, Inc. (ONCR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate r...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announc...
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announce...
